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Abstract Various approaches have been used to model hu-
man Graves’ disease in mice, including transfected fibro-
blasts, and plasmid or adenoviral immunisations with the ex-
tracellular A subunit of the human thyrotropin receptor
(TSHR). Some of these models were only observed for a short
time period or were self-limiting. A long-term model for hu-
man Graves’ disease was established in mice using continuing
immunisations (4-weekly injections) with recombinant adeno-
virus expressing TSHR. Generation of TSHR binding cAMP-
stimulatory antibodies, thyroid enlargement and alterations,
elevated serum thyroxin levels, tachycardia and cardiac hyper-
trophy were maintained for at least 9 months in all Ad-TSHR-
immunised mice. Here, we show that these mice suffer from
orbitopathy, which was detected by serial orbital sectioning
and histomorphometry. Attempts to treat established Graves’
disease in preclinical mouse model studies have included
small molecule allosteric antagonists and specific antagonist
antibodies which were isolated from hypothyroid patients. In
addition, novel peptides have been conceived which mimic
the cylindrical loops of the TSHR leucine-rich repeat domain,
in order to re-establish tolerance toward the antigen. Here, we
show preliminary results that one set of these peptides im-
proves or even cures all signs and symptoms of Graves’ dis-
ease in mice after six consecutive monthly injections. First
beneficial effects were observed 3–4 months after starting
these therapies. In immunologically naïve mice, administra-
tion of the peptides did not induce any immune response.
Keywords Thyreotropin receptor . Graves’ disease .
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Background: Clinical Features of Disease
Graves’ disease is a common antibody-mediated autoimmune
condition targeting the thyrotropin-TSH receptor (TSHR) in
the thyroid gland, resulting in hyperthyroidism [1], with an
annual incidence of 15–80 per 100,000 persons throughout
the world. A quality of life (QOL) assessment showed that
the disease is accompanied by a reduced vital and mental
QOL for several years despite treatment according to current
standards [2]. If left untreated, Graves’ leads to significantly
increased morbidity and mortality [2].
Animal Models of Disease—Thyroid Alterations
and Hyperthyroidism
The antibody-mediated autoimmune condition targeting the
TSH receptor (TSHR) in the thyroid gland which results in
hyperthyroidism can be replicated in mouse models [3],
preferably in TSHR-immunised mice. This was initially
observed in the transfected fibroblast model [4], in which
about 25 % of injected mice developed hyperthyroidism,
and after recombinant dendritic cell injections [5]. After some
failed efforts to use plasmid immunisations, adenovirally
induced immunisation with the A domain of TSHR
(Ad-TSHR) in BALB/c mice was successfully established to
induce a mouse model of Graves’ disease [3, 6, 7]. The use of
adenovirus was more effective than use of plasmid transfec-
tion in most studies, with the exception of a protocol of
electroporation [8, 9]—four 3-weekly immunisations over a
total period of 3 months. After plasmid electroporation,
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long-term expression of stimulatory anti-TSHR antibodies
and persistent thyroid enlargement was described [10].
However, this disease model seems to have caused a relevant
mortality of the investigated mice starting 4 months after the
last electroporation [10].
The establishment of various protocols to induce Graves’
disease led to the challenge of comparing these models [3, 7].
Elevated T4 levels, stimulating anti-TSH antibodies, goiter
and typical histological alterations, were considered to be es-
sential characteristics of any model which should be relevant
for human disease [3, 7], and most were replicated already in
early reports [11, 12].
Long-term persistence of the models using adenoviral gene
transfer was not clearly described in most of these studies.
Prolongation of the protocol based on three adenovirally in-
duced immunisations over 6 weeks and measurements after
20 weeks instead of 10 weeks also led to disease induction
[13]. The immunisations with recombinant TSHR were stud-
ied in both, wild-type or TSHR-transgenic mice. Although the
formation anti-TSHR antibodies with binding activity was
consistently observed after 20 weeks in these virus-
immunised mice, the potency of the resulting antibodies to
stimulate cAMP considerably diminished or even disappeared
during the course of the experiment (50 % positive at the end
of the experiment), and no T4 elevation nor thyreocyte hyper-
plasia was observed [13]. Regulatory T cell depletion and
administration of adjuvant in TSHR-transgenic mice did not
reliably induce Graves’ disease [14].
In a recent study [15], we extended these existing models
of adenoviral TSH receptor immunisation by using a novel
protocol in which regular injections were continued for
9 months, in order to permanently boost antibody production
in mice. This protocol was established in parallel to a previous
study which successfully introduced a long-term disease mod-
el of cardiomyopathy caused by anti-β1 receptor antibodies in
rats [16, 17].
This extended protocol of three 3-weekly immunisations—
followed by regular four weekly boosts led to generation of
TSH-binding antibodies, which stimulated TSHR-dependent
cAMP activity and induced thyroid hyperplasia and marked
histological alterations for at least 9 months, as well as con-
sistent thyroxin (T4) release.
Anti-TSHR Antibody Titres and Capacity
to Stimulate cAMP in Test Cells
Anti-TSHR antibodies were determined from serum samples
using three different assays. These assays included the current
gold standard Bthird generation^ immunoassay, which detects
the ability of the respective mouse sera to inhibit the binding
of the monoclonal Graves’ patient antibodyM22 to the TSHR
(RSR-Cobas Roche), which is most often used to identify
Graves’ disease in humans. This assay was reported to iden-
tify Graves’ patients with a specificity and sensitivity of
>97 % [18, 19]. So, functionally active anti-TSHR antibodies
observed in immunised mice are readily detected by this same
assay. Use of identical assays also allowed to compare abso-
lute titre values. Mean anti-TSHR antibody titres increased
progressively during the course of the study in Ad-TSHR-
immunised animals, as determined by third generation
ELISA.
Very comparable results were obtained with a second-
generation assay using competition against the physiological
agonist TSH [15].
In addition, the stimulatory activity of these antibodies was
determined as the capacity of mouse serum samples to stimu-
late TSHR-dependent cAMP levels in test cells [15]. This
capacity was markedly and consistently increased in serum
samples taken from Ad-TSHR-immunised animals but was
never detected in sera from the mock-immunised group.
Sizes and Patho-histological Changes of the Thyroid,
Serum Thyroxin Levels
Macroscopic investigation showed clearly increased thyroid
sizes in mice which had received nine immunisations of re-
combinant adenovirus encoding TSHR (Ad-TSHR). Thyroid
volumes were determined from the sums of the areas of
standardised sections throughout the thyroid. In addition, con-
sistent and marked thyroid hyperplasia was observed.
Histological features included increased thyrocyte length and
cuboid epitheloid hyperplasia after 7 months, and a degenerate
image with prominent infoldings of follicles, smaller follicle
size and vacuolisation at 9 months [15]. This led to fractioning
of thyroid follicles, and corresponding smaller follicle and
colloid sizes [15]. This degenerate histological image
contrasted with the normal aspect of intact follicles and nor-
mal colloid size of mock-immunised animals.
Mean T4 levels in the group in Ad-TSHR-immunised an-
imals were consistently and significantly higher than controls,
if 1010 plaque-forming units (pfu) of recombinant Ad-TSHR
were used for immunisation [15].
Graves’ Orbitopathy
Animal models of Graves’ disease have been tested especially
for their ability to reproduce orbital histology and to quantify
retro-orbital fibrosis which represents an important hallmark
of clinical disease in humans. After some prior studies had
failed to find such alterations in TSHR-immunised mice, his-
tological investigation after transcranial dissection document-
ed altered orbital muscle fibrosis in single mice after electro-
poration and plasmid gene transfer of the TSHRA domain [8].
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Interestingly, these orbital alterations did not occur in animals
which had been transfected with the gene coding for the
insulin-like growth factor receptor-1 (IGF1R) which has also
been implied in the pathogenesis of Graves’ orbitopathy, al-
though relevant anti-IGF1R antibody titres were documented
in these animals. A further elegant study by the same group [9]
also documented inflammatory alterations in the orbitae of
TSHR-immunised animals histologically. Additional nuclear
resonance imaging was used to assess orbital and orbital mus-
cle volumes serially over time and showed clear increases of
both parameters [9].
Based on these studies, these authors hypothesised that
orbital pathologies do not occur after adenoviral TSHR
immunisation, but only after TSHR plasmid immunisation
[20]. However, this conclusion was based on the analysis of
papers studying short-term adenoviral immunisation
protocols.
Since we had observed that long-term repeated adenoviral
TSHR immunisations seem to induce a more stable Graves’
phenotype inmice [15], wewished to investigate the orbitae in
a follow-up study using an identical protocol using nine
immunisations with 1010 pfu Ad-TSHR. Analysis of orbital
changes was carried out histologically using a protocol which
included many steps which had already described in the pre-
vious studies [8, 9], including Masson’s trichrome staining,
but added a few modifications:
For orbital preparations after euthanasia, complete dissec-
tions of the orbital and periorbital areas included all orbital
tissues, eyelids and adjacent tissues. Consecutively, the tissues
were trimmed, fixed and decalcified by placing in EDTA so-
lution for 48 h, then washed 3× with phosphate-buffered sa-
line (PBS). Then, the tissues were immerged into a sucrose
solution for 24 h at 4 °C, followed by fine-trimming and
incubating in optimum cutting temperature (OCT) formula-
tion. Serial coronary sections (7 μm thick, 0.63 mm apart)
were obtained (Fig. 1a). For Masson’s staining, sections were
placed in Bouin’s fixation solution at 20 °C overnight and
washed for 2 h, and then treated with Masson-Goldner
trichrome staining kits.
The orbi ta l sec t ions were captured with an
Axiovision digital cam system. Fibrosis areas in the
extra-orbital adipose tissues and extra-orbital muscle
(EOM) regions were indicated by their green colour
after Masson’s trichrome staining. Digitised image anal-
ysis of the green colour pixels areas enabled reliable
quantification of fibrosis, as had been validated previ-
ously [21]. Accordingly, all fibrotic tissue throughout a
whole orbital section was quantified, and results of all
sections were added in the end to yield a total fibrosis
volume (mm3) of each investigated orbita.
As an extension of our previous results [15], we now show
in a follow-up study that a significant increase of retro-orbital
fibrosis is observed in mice if adenoviral TSHR
immunisations are maintained using the identical protocol
for several months. Figure 1b shows that this increase occurs
in both, right and left orbitae. These findings complement the
previous studies in which orbital pathology was assessed by
magnetic resonance (nuclear spin) imaging MRI [9].
Cardiac Involvement in Patients
A clinical feature of all forms of hyperthyroidism is
cardiac involvement which is directly caused by the
action of thyroid hormones on nuclear receptors within
the myocardium [22]. Hence, contractility is increased,
and a hypertrophic form of cardiomyopathy [23], as
well as tachycardia is observed in these patients. Heart
rates at rest are increased and represent a reliable mark-
er of disease severity [22, 23]. Atrial fibrillation occurs
in 5–15 % of patients [24], and palpitations are among
the most reported symptoms defining disease burden.
Increased cardiovascular morbidity and mortality have
been reported in patients with both, overt or subclinical
hyperthyroidism [24–27]. Hyperthyroid patients suffer-
ing from Graves’ disease are at especially increased car-
diovascular risk [28]. Graves’ disease results in in-
creased morbidity and mortality [2] mainly due to car-
diac complications [22]. Twenty-four-hour ECG moni-
toring showed that heart rate is constantly increased
during the day [23].
Cardiac Involvement in Animal Disease Models
of Graves’ Disease
Effects of Ad-TSHR immunisation were reported in three
rhesus macaque monkeys which were successfully treated
with seven consecutive injections over 20 weeks [29].
Clinical investigation of these three animals also indicated
increased heart rate (no details on method were given). In a
previous study, we showed that also in Ad-TSHR-immunised
hyperthyroid mice, significant tachycardia occurred [15].
Most of the evaluated ECGs related to sinus tachycardia—
short stretches of arrhythmia occurred, but could not be un-
equivocally related to atrial fibrillation, perhaps owing to reg-
istration quality.
Macroscopical investigation and preparation of mouse
hearts upon necropsy revealed significantly increased heart
weights after Ad-TSHR immunisation [15]. Additionally, cal-
culation of myocardial volumes by adding up digitised cross-
sectional LV areas which were calculated from standardised
heart sections showed increased cardiac ventricular volumes.
Histological assessment revealed signs of cardiomyocyte
hypertrophy and cardiomyopathy. These included increases
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in cell size and thicker myocardiac fibres in the HE-stained
sections of the Ad-TSHR-immunised animals.
Table 1 shows an overview on mouse models of Graves’
disease especially with regard to cardiac and orbital
involvement.
Correlations
Correlations were determined for end-of-study results in
TSHR-immunised mice. A study on plasmid-induced
TSHR immunisation found reasonable correlations be-
tween thyroxin T4 value and anti-TSHR antibody titres
[10]. Also, after Ad-TSHR immunisation, we found
high correlations coefficients >0.7 for thyroid sizes vs.
thyroxin (T4) levels, vs. anti-TSHR titre levels and vs.
heart weights and heart rates at the end of the observa-
tion period [15]. In contrast, thyroid sizes did not cor-
relate as well with the absolute cAMP-stimulatory ca-
pacities of the anti-TSHR antibodies on test cells, which
were generally not well correlated to the other
parameters.
These findings indicate that the animal model is consistent-
ly characterised by generation of specific anti-TSHR antibod-
ies whose levels in single animals impact on the amount of
thyroid enlargement and on serum T4 levels as well as on the
cardiac consequences of disease. We also conclude from these
data that effects of anti-TSHR antibodies on target cells dif-
ferent from cAMP stimulation should be relevant, because the
biological effect of these antibodies is not precisely predicted
just by measuring their capacity to stimulate cAMP levels in
test cells. Such alternative second messenger systems could
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Fig. 1 Histological investigation of orbital sections. a Representative
macroscopic images. Representative images of coronary sections of a
mouse orbita and neighbouring tissues. The sections were taken at
defined distances from the mouse bregma. Interstitial connective tissue/
fibrosis was then stained in green (Masson’s trichrome stain). For clarity,
both HE-stained sections (left panels) and Masson’s stained sections
(right panels) are shown next to each other. b Effect on digitised analysis
of retroorbital tissue. The effects on severity of retro-orbital fibrosis were
evaluated in histological sections. The measurements were carried out in
immunised mice treated by either four weekly injections with control Ad-
GFP (Bmock-immunised^) or four weekly injections with Ad-TSHR
(BGraves’ diesease^). N = 10 mice were investigated in each group. The
mean total fibrosis volumes of each right and left orbita, as assessed by
digitised image analysis of all sections, and consecutive integrations, are
shown with SEM. Differences between groups were tested by ANOVA,
*p < 0.05 compared to the TSHR-immunised group
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depend on stimulation of Gq and consequent activation of
phospholipase C or other intracellular enzymes but might also
imply activation of Gi-dependent pathways.
Therapeutic Approaches
Graves’ disease is often initially treated by giving thyreostatic
drugs, such as carbimazol, followed by radioiodine therapy
[30] or surgical removal of the thyroid gland. All these treat-
ment options are characterised by relatively high relapse rates
and significant side effect profiles [31].
Treatment of refractory disease cases and of accompanying
ophthalmopathy/orbitopathy is especially challenging.
Ophthalmopathy occurs in almost half of all Graves’ pa-
tients—up to 16 per 100,000 women per year in the general
population [32]. In this condition, anti-TSHR antibody titres
and relapse rates are especially high [32]. These patients must
frequently be treated with high doses of intravenous corticoids
over many weeks, which even incur more side effects [33].
Therefore, novel treatment options have been explored in re-
cent years. A reduction of B lymphocytic cell counts can be
achieved by giving the anti-CD20 antibody rituximab
(MabThera®, anti-CD20 Mab). Driven by the hypothesis that
Graves’ disease is majorly a B cell-mediated condition, a re-
cent randomised double-blind trial showed an advantage for
the rituximab-treated group [34], whereas another did not
(NCT 00595335, ref. 33), perhaps due to frequent side effects
of the therapy.
Recent Novel Experimental Therapies Which Were
Investigated in Mouse Disease Models
Studies in Ad-TSHR-immunised mice established that the
model can be used to investigate immunotherapeutic interven-
tions: a mouse anti-CD20 antibody, an analogue of rituximab
[35] and the B cell activating factor fusion protein TACI-Fc
(atacicept, ref. [36]), which can block the B cell activating
factor BAFF (also known as B lymphocyte stimulator,
BLys) on these cells. Many of these rather broad-range B
lymphocyte-directed therapies have been successfully
established in the treatment of a variety of autoimmune disor-
ders and reflect the increasing recognition that not only regu-
latory T lymphocytes but also B lymphocytes play an impor-
tant role in autoimmunity [37, 38].
Further work at FIRS lab, RSR, Cardiff, has identified inhib-
itory monoclonal TSHR-binding antibodies such as K1-70 which
were isolated from patient blood and which compete for the stim-
ulatory action of Graves’ patients’ autoantibodies [39]. They can
counteract hyperthyroid states in M22-injected rats [39].
In addition, small molecule TSHR antagonists were con-
ceived, but so far, only tested ex vivo and in healthy mice
[40–42]. These compounds such as ANTAG3 are specific
allosteric regulators of the TSHR hinge region but seem to
act only at fairly high in vivo doses. In addition, all suffer from
some cross-reactivity with the luteinising or follicle-
stimulating (LH or FSH) hormone receptors at least at the high
doses which are needed for in vivo effects, and their toxico-
logical characterisations have so far not been reported.
Table 1 Overview on major
mouse models of Graves’ disease





Cells which stably express TSHR
Transfected fibroblast model About 25 % n/d n/d [4]
Recombinant dendritic cells Low incidence n/d n/d [5]
TSHR DNA (plasmid) administration
Intramuscular injection 17 % n/d Yes [69]
Intramuscular injection w/ G2
plasmid
None n/d Yes [70]
Electroporation, follow-up
3 months
High incidence n/d Yes [8, 9, 20]
Electroporation, follow-up
9 months
High incidence n/d n/d [10]
Adenovirus encoding TSHR (A domain)
Up to three immunisations over
4 months
25–70 % n/d No [3, 6, 7, 11, 12]





Nine immunisations over 9 months High incidence Yes Yes [15]
+ Data shown
here
n/d not determined/not reported
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Prospect of Allergen-Specific Immune Therapies
in Patients
In general, treatment with broad-range immunosuppressive
drugs may cause serious side effects so that, in addition,
antigen-specific therapies have been conceived to induce tol-
erance in a variety of autoimmune conditions. For many de-
cades, specific immune therapies (SIT) have been established
successfully for the treatment of allergic-atopic diseases.
Recombinant peptides are being increasingly used for such
hyposensitisation therapies (SIT) which offer significant ad-
vantages over the classical raw allergen extracts [43–45].
Effects on T Lymphocytes
In analogy to SIT for allergic diseases, peptides to in-
duce tolerance have been investigated in a variety of
other conditions and been linked to regulatory T cells.
Generally, specific immunotherapy for autoimmune dis-
eases lagged behind until the discovery that T helper
lymphocytes are activated by peptides bound to major
histocompatibility (MHC) class II proteins [46]. This led
to the design of peptides that selectively target immune
cells without risking the activation of self-reactive cyto-
toxic T or B lymphocytes [43]. Exposure to a peptide
which stimulates self-reactive T helper lymphocytes can
mitigate the disease, which may be explained by the
Btwo-signal^ rule of T cell activation [46, 47]: Self or
foreign antigens must be broken down into peptides,
which bind MHC class II proteins and must be
displayed at the surface of antigen-presenting cells
(APCs) to activate effector cells. This step is known
as signal 1. The antigen-presenting cells must also up-
regulate costimulatory molecules, such as CD80 and
CD86, to provide the second signal required for T help-
er cell survival and proliferation.
At conditions when T helper cells receive signal 1, but not
signal 2, they induce a state of unresponsiveness known as
anergy [48]. In a recent publication, T helper cells treated with
nanoparticles which had been coated with a peptide bound to
MHC class II proteins (pMHC-NP treatment) triggered signal
1 alone [49, 50]. This concept has been shown to not only
induce anergy but also drive T helper cells to differentiation to
what resembles regulatory T cells which reduce immune re-
sponses [49, 50].
Altered regulation of immune checkpoint interaction be-
tween CD 28 and CD80/86 and CTLA-4 has been implied
in these processes [51]. If applied subcutaneously, success-
ful therapy has been related to consecutive antigen dose
escalation and to local release of interleukin-10 from lym-
phocytes [52, 53]. Although immune-disease-triggered epi-
tope spreading might have occurred at the time when such
a therapy is initiated [54], Bbystander suppression^ of in-
dependent epitopes has been implied in therapeutic effects
[53]. Although these therapies have not all been success-
ful, they are still being pursued by researchers in various
fields [55, 56].
Fig. 2 Antigen-specific peptides
can induce peripheral tolerance.
The figure shows that
administration of peptides can
induce peripheral T or B
lymphocyte anergy if presented to
antigen-presenting immune cells
in the absence of a co-stimulatory
signal
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Novel Approach for Antigen-Specific Therapy:
Intravenous Administration of High Doses
of Conformational Peptides
As a novel option for antigen-specific therapy, the
group of Mart in Lohse and Roland Jahns has
established intravenous administration of fairly high
doses of immunogen-mimicking cyclic peptides for the
treatment of anti-β1-adrenergic receptor-mediated auto-
immune cardiomyopathy [16, 57–59]. The investigation
of peptide-treated animals showed that the beneficial
therapeutic effects were related to a marked decrease
of antigen-specific pre-B lymphocytes in the spleen
[57]. This phenomenon can be observed if these cells
are exposed to the specific antigen in the absence of a
co-stimulatory signal, which again refers to the lack of
interaction between CD80/86–B7.1/2 and CD28.
Figure 2 very schematically shows the possible
modes of action of such peptides, i.e. to induce periph-
eral tolerance. Tolerogenic peptides can reduce immuno-
genic T lymphocytes and induce specific subsets of
tolerogenic (regulatory) T lymphocytes. Simultaneously/
alternatively, they can reduce antibody-producing lym-
phocytes and pre-B lymphocytes by anergy. Recent
studies have implied induction of regulatory T helper
subsets instead of T lymphocyte anergy during this pro-
cess [46], documenting such changes not only in ro-
dents but also in human cells.
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Fig. 3 a Time schedule of the
currently on-going therapeutic
study. The figure shows the time




structure of the thyroid
stimulating hormone (TSH)
receptor. Peptides were derived
from the loop structure of the
leucine-rich repeat domain of the
extracellular A subunit of the
TSHR, as marked in blue colour
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Effects on B Lymphocytes
In parallel to T lymphocyte anergy, B cell anergy has been
described in several pivotal studies in which it was shown to
require constant B cell receptor (BCR) occupancy with rather
high levels of (self) antigen [60, 61]. After initial characteri-
sation in rodents, it has also been reconfirmed in human im-
mune cells [62, 63] and been explained by chronic low-level
BCR cross-linkage [63]. In addition, high-level BCR cross-
linkage in the absence of co-stimulatory signals leads to clonal
B cell deletion after acute high level antigen exposure [63].
Originally, clonal anergy was proposed as a way to inactivate
B cells stimulated early in development when only
autoantigens would be presented [60]. Further studies have
documented fine tuning of B lymphocyte responsiveness
and inactivation of self-reactive B cell clones by anergy
Fig. 4 Effect of novel peptides on anti-TSHR antibody titres. The effect
of peptide therapy on time course of anti-TSHR titres, as measured by
third generation ELISA. The measurements were carried out in Ad-
TSHR-immunised mice treated by either four weekly injections with
vehicle (BGraves’—no therapy^), or administrations of a peptide
(1 mg/kg body weight—BGraves’ + peptide^). In addition, age-matched
immunologically naïve mice were investigated (Bhealthy^). N = 10 mice
were investigated in each group. Data are represented as mean ± SEM.
Significance over time was tested by analysis of variance (ANOVA) of
groups at given time points and controlled by ANOVA for repeated
measurements within one group, followed by LSD post hoc testing.
Asterisk indicates statistical significance (p < 0.05) compared to the
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Fig. 5 Effect of peptides on macroscopically measured thyroid size. The
effects of peptide therapy on thyroid sizes were investigated at the end of
the experiment. The measurements were carried out in Ad-TSHR-
immunised mice treated by either four weekly injections with vehicle
(BGraves’—no therapy^) or administrations of peptide (1 mg/kg body
weight). In addition, age-matched immunologically naïve mice were
investigated. N = 10 mice were investigated in each group. The mean
thyroid sizes in mm3 are shown with SEM. Differences between groups
were tested by AVOVA followed by post hoc LSD testing. Asterisk
indicates statistical significance (p < 0.05) compared to the TSHR-
immunised group treated with only NaCl
**
*
Fig. 6 Effect on serum thyroxin (T4) levels. The effects of peptide
therapy on serum thyroxin levels were evaluated. The measurements
were carried out in Ad-TSHR-immunised mice treated by either four
weekly injections with vehicle (BGraves’—no therapy^) or of a peptide
(1 mg/kg body weight), or in age-matched immunologically naïve mice.
Data are represented as means ± SEM. N = 10 mice were investigated in
each group. Significance over time was tested by analysis of variance
(ANOVA) of groups at given time points and controlled by ANOVA
for repeated measurements within one group, followed by LSD post
hoc testing. *p < 0.05 and **p < 0.01, compared to the TSHR-
immunised group treated with only NaCl
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[64]. This phenomenon seems to play a relevant role in a
variety of immune phenomena and seems to be an attractive
mechanism for the treatment of several B lymphocyte-
mediated diseases. For more than a decade, the direct effects
of B lymphocytes in autoimmune disease have been increas-
ingly recognised. Their importance is highlighted by the fact
that auto-antibodies can often be detected in these diseases
many years before symptoms evolve (i.e. in thyroid autoim-
mune diseases) and that disease manifestations can be trans-
ferred across the placenta, which should be due to the effect of
pathogenic maternal antibodies on embryos [37].
Similar to what has been described for T lymphocytes,
antigen-mimicking peptides may be presented to these im-
mune cells via major histocompatibility class II (MHC II)-
dependent antigen presenting cells in the absence of co-
stimulatory signals and thereby reduce their activation.
Antigen-Specific Immunotherapy for Thyroid
Disease in Animal Models
For several years, studies in Ad-TSHR-immunised mice have
been used to investigate antigen-specific immune therapies as
novel interventions: An early specific immune therapy ap-
proach in mouse models of Graves’ disease relied on intrana-
sal administration of linear peptides as T cell epitopes which
however did not prove successful [65]. Alternatively, a soluble
form of the TSHR A domain (expressed as his-tagged protein
in CHO cells) was shown to induce tolerance in mice when
given before subsequent Ad-TSHR immunisations [66].
However, a single intra-muscular or subcutaneous injection
of this protein was not effective on established disease in this
short time model of Ad-TSHR immunisations: Anti-TSHR
titres did not decrease, but rather increased, and T4 thyroxin
levels were unaltered in these mice.
In another study, intra-peritoneal or intra-muscular chal-
lenges of Ad-TSHR on neonatal mice had induced tolerance
against further immunisations in adulthood [67]. However,
such a virus-mediated prophylaxis may be difficult to estab-
lish in human medicine.
Last not least, another approach identified peptides to in-
duce tolerance after selecting specific T cell epitopes which
were optimised in HLA-DR 2-transgenic mice. Subcutaneous
administration of the peptide ATX-GD-5D-K has been shown
to reduce anti-TSHR antibody production after consecutive
adenoviral TSHR immunisation in a similar mouse model
[68], i.e. in a prophylactic setting. The concept is that soluble
peptides bind to empty MHC receptors and selectively trigger
activation of interleukin-10-positive T lymphocytes which
specifically suppress pathogenic T helper cells [68]. The au-
thors have so far not published data on treatment of
established disease nor on thyroid size or hyperthyroidism.
Intravenous Conformational Epitope Peptide
Therapy for Thyroid Disease
In parallel and as an extension to these approaches, we sought
to establish another antigen-specific therapeutic concept for
anti-TSHR-mediated disease. In parallel to the studies on β
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Fig. 7 Histological investigation of orbital sections and digitised analysis
of retroorbital tissue: effects of novel peptides. The effects of peptide
therapy on severity of retro-orbital fibrosis were evaluated in histological
sections. The measurements were carried out in mice which had either
received four weekly injections with vehicle (BGraves’—no therapy^) or
of a peptide (1 mg/kg body weight), or in age-matched immunologically
naïve mice. The mean total fibrosis volumes of each right and left orbita,
as assessed by digitised image analysis of all sections, and consecutive
integrations, are shown with SEM.N = 10mice were investigated in each
group. Differences between groups were tested by ANOVA, *p < 0.05
compared to the TSHR-immunised group treated with only NaCl. Also,
results of TSHR-immunised mice differed significantly (p < 0.05) from
healthy controls
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adrenergic receptors [57], we designed peptides which mimic
the tertiary structure of the single cylindrical loops of the
TSHR leucine-rich repeat domain (LRD). TSHR and β-
adrenergic receptors share some common features since they
are both G protein-coupled receptors. Figure 3b shows the
structure of the LRD and indicated how novel peptides were
derived from the native structure of the receptor.
These peptides were tested for their potency to in-
duce tolerance in TSHR-immunised diseased mice after
repeated intravenous administration of target doses—to
mitigate disease manifestations such as thyroid enlarge-
ment, hyperthyroidism and retro-orbital fibrosis. To this
end, an identical protocol was used as described before
[15], and complemented by therapeutic peptide adminis-
trations after week 11, when thyroid disease had fully
evolved. All peptides were administered six times at
four weekly intervals. Please see Fig. 3a for an over-
view on the protocol of immunisations and of therapeu-
tic peptide administrations.
Our preliminary experiments show that a set of peptides
which mimic a loop of the leucine-rich repeat domain of
TSHR suppressed or at least stabilised the titres of TSH-
binding antibodies despite continuing immunisations (Fig. 4).
Thus, established thyroid disease was successfully
treated in these animals. To our knowledge, this is the
first report on such findings after antigen-specific ther-
apy. Increased thyroid sizes were reduced after 6 months
of peptide therapy (Fig. 5). In parallel, also thyroid hy-
perplasia and histological alterations were markedly re-
duced. Elevated thyroxin (T4) levels were reverted to
normal values, starting 15 weeks after initiation of pep-
tide therapy (Fig. 6).
Initial results of a follow-up study also suggest that retro-
orbital fibrosis was reduced, suggesting a positive effect on
Graves’ orbitopathy (Fig. 7). These findings represent an in-
teresting complementation of previous preclinical studies on
Graves’ disease models, since such a therapeutic effect has not
yet been shown in animal models. On the other hand, patients
with Graves’ orbitopathy are especially hard to treat.
Since the investigated peptides were derived from
only one of the several possible epitopes of which the
LRD of the TSHR is composed, the feasibility to block
polyclonal immune responses in different mice suggests
that Blinked suppression^ (sometimes also termed by-
stander suppression) plays a role in the observed effects,
although so far only described for T lymphocyte-
directed therapies.
In addition, administration of the same peptides at
identical dosings (six monthly administrations) in
immunogically naïve mice did not result in any immune
reactions. No anti-TSHR titres (as measured with the
third-generation assay) were observed in these animals at
any time during the experiment.
Summary and Conclusions
In summary, a long-term disease model of Graves’ disease has
been established, which stably features many hallmarks of
human disease including orbitopathy. Specific peptides which
mimic loops of the leucine-rich domain hold promise as a
future treatment of Graves’ disease. After repeated monthly
administrations, they reduced thyroid size, elevated serum T4
levels, tachycardia and retro-orbital fibrosis. In peptide-treated
animals, the titres of TSHR-binding antibodies were sup-
pressed or at least s tabi l ised despite continuing
immunisations.
So, current therapeutic approaches to treat autoimmune
diseases include administration of increasing doses of
allergen-mimicking peptides subcutaneously [53] or of high
doses of conformational allergenic epitopes intravenously,
which seems to primarily induce B cell anergy [57]. The
mechanisms which may explain this immunological tolerance
to target antigens remain to be exactly determined—they in-
clude B lymphocyte and/or T lymphocyte anergy and regula-
tion of T helper cell populations, as well as clonal B cell
deletion.
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